| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
No specific gene target. siRNA Negative Control is designed to have no significant homology to any known gene in the species of study, thus it does not target any specific mRNA for degradation. It is used to control for non-specific effects of siRNA transfection, including cellular stress responses, interferon activation, and off-target gene modulation.
|
|---|---|
| ln Vitro |
In vitro, siRNA Negative Control shows no specific gene silencing activity against any intended target mRNA. It is used in RNA interference experiments to demonstrate that the observed phenotypic changes are due to specific knockdown of the target gene rather than non-specific effects of siRNA transfection. The control should not induce significant changes in cell viability, proliferation, or gene expression profiles compared to mock-treated or non-targeting control.
|
| ln Vivo |
In vivo, siRNA Negative Control is used to assess off-target and non-specific effects of siRNA administration in animal models. It serves as a critical control for experiments evaluating therapeutic siRNA candidates, helping to distinguish on-target efficacy from sequence-independent toxicity or immune activation. No therapeutic activity is expected or intended.
|
| Enzyme Assay |
Non-cell-based binding/activity assay is not applicable for a negative control siRNA. However, sequence verification can be performed by HPLC or mass spectrometry to confirm the composition. The absence of significant homology to human, mouse, or rat transcriptomes should be verified by BLAST search against reference genomes to confirm non-targeting status.
|
| Cell Assay |
Cell culture control protocol: Target cells (e.g., HeLa, HEK293, or primary cells) are seeded in 6-well or 96-well plates (50-70% confluency). siRNA Negative Control is transfected using a suitable transfection reagent (e.g., Lipofectamine RNAiMAX) at concentrations matching the experimental siRNA (typically 5-50 nM). After 24-72 hours, cells are harvested for qRT-PCR or Western blot to confirm no off-target gene modulation. Cell viability is assessed by MTT or CellTiter-Glo.
|
| Animal Protocol |
Animal study protocol (example): Mice receive siRNA Negative Control formulated in lipid nanoparticles or saline at doses matching the therapeutic siRNA (e.g., 0.5-5 mg/kg) via intravenous or local administration. Blood and tissue samples are collected at various time points for assessment of cytokine levels (IFN-alpha, IL-6), liver enzymes (ALT, AST), and histological examination to evaluate non-specific immune activation. Body weight and general behavior are monitored daily.
|
| ADME/Pharmacokinetics |
siRNA Negative Control has no pharmacological or therapeutic activity, so PK studies are generally not applicable. However, as a nucleic acid, its tissue distribution and clearance can be measured using labeled control siRNAs (e.g., fluorescent or radiolabeled). Typically, siRNAs are rapidly cleared from circulation by renal filtration and nucleases, with a half-life of minutes to hours.
|
| Toxicity/Toxicokinetics |
Toxicity of siRNA Negative Control is generally minimal. Non-targeting siRNAs may induce sequence-dependent or sequence-independent off-target effects including immune stimulation (via Toll-like receptors), saturation of the RNAi machinery, or unintended microRNA-like off-target gene regulation. In animal studies, high doses may cause hepatotoxicity or cytokine release. Proper controls are essential to identify such effects.
|
| Additional Infomation |
siRNA Negative Control is an indispensable reagent in RNA interference research. It is typically a scrambled sequence with the same nucleotide composition as the experimental siRNA but lacking homology to any known target. Universal negative control sequences are available commercially. The control should be matched to the species of study. Transfection efficiency should be validated using a positive control (e.g., siGAPDH). Store as dry powder at -20degC.
|
| Molecular Weight |
13323 ( AS: 6586.9; SS: 6736.1 )
|
|---|---|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
